Sygnature Discovery, a drug discovery CRO, acquired NuChem Sciences, adding integrated drug discovery phase services. The transaction expands Sygnature’s global footprint and business operations with discovery expertise in the North American market. Together the companies provide drug discovery expertise to support customer programs from target validation through to candidate selection, combining North American and UK operations. NuChem Sciences employs more than 300 staff across cen...